Publications by authors named "Jordan Hutson"
Article Synopsis
- Inotropic support is commonly used for patients with cardiogenic shock (CS), but existing data on arrhythmic events in these patients is potentially biased.
- The DOREMI trial compared the effects of dobutamine and milrinone on patients, assessing the incidence and impact of arrhythmias on in-hospital outcomes.
- Nearly half of the patients experienced arrhythmic events, with ventricular arrhythmias linked to higher mortality, while several patient characteristics could help identify those at greater risk for such complications.
Article Synopsis
- Cardiogenic shock (CS) is a serious condition linked to high rates of complications and death, and the DOREMI trial looked at how sex might affect outcomes in CS patients.
- In a detailed analysis of 192 participants, researchers found that female patients had similar rates of severe outcomes as male patients, including death and need for mechanical support.
- Ultimately, no significant differences were seen in the clinical outcomes between males and females in the study, regardless of the type of treatment (dobutamine or milrinone) used.
Background: Cardiogenic shock is associated with substantial morbidity and mortality. Although inotropic support is a mainstay of medical therapy for cardiogenic shock, little evidence exists to guide the selection of inotropic agents in clinical practice.
Methods: We randomly assigned patients with cardiogenic shock to receive milrinone or dobutamine in a double-blind fashion.
Background: Cardiogenic shock (CS) is associated with high mortality. We report on a "Shock Team" approach of combined interdisciplinary expertise for decision making, expedited assessment, and treatment.
Methods: We reviewed 100 patients admitted in CS over 52 months.
Background: Periprocedural blood transfusions are associated with long-term mortality in patients undergoing transcatheter aortic valve implantation (TAVI). We sought to assess the impact of a preoperative blood conservation approach in treating anemia and preventing blood transfusions in patients undergoing TAVI.
Methods: Our cohort consisted of all patients evaluated in our structural heart clinic between January 1, 2012 and December 31, 2014.